Overall Survival With Second-Line Pembrolizumab in Patients With Non–Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data
Thomas Jemielita(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cong Chen(Fujian University of Traditional Chinese Medicine), Bilal Piperdi(Université Toulouse III - Paul Sabatier), Thomas Burke(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoyun Li(Nanjing University), Wei Zhou(Broad Institute)
Cited by 15
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
|New England Journal of Medicine|2011|1.1k